Dr. Lillian Barra, MD (UWO) MPH (Harvard)
Department of Medicine, Division of Rheumatology
Department of Microbiology and Immunology
Office: Rm 220, SDRI
Fax: 519 661-3499
The major research interest of Dr. Barra's laboratory is the role of autoantibodies in Rheumatoid Arthritis (RA) and its associated complications, in particular vascular disease. We aim to investigate the immune mechanisms contributing to the increased rate of cardiovascular disease in patients with RA. The research is translational involving mouse models of RA and atherosclerosis, biomaker studies as well as epidemiologic studies with participation in various cohort studies.
Barra L, Summers K, Bell D, Cairns E. Serum cytokine profile of unaffected First Degree Relatives of Rheumatoid Arthritis patients. J Rheumatol. 2014 Feb;41(2):280-5
Scinocca M, Bell DA, Racape M, Joseph R, Shaw G, McCormick JK, Barra L, Cairns E. Homocitrullinated fibrinogen: an antigen specific to rheumatoid arthritis and a target of anticitrullinated protein/peptide antibodies. J Rheumatol. 2014 Feb;41(2):270-9.
Barra L, Scinocca M, Saunders S, Bhayana R, Rohekar S, Recape M, Coles R, Cairns E and Bell D. Anti-Citrullinated Protein Antibodies (ACPA) in Unaffected First Degree Relatives of Rheumatoid Arthritis Patients. Arthritis Rheum. 2013 Jun;65(6):1439-47.
Barra L, Bykerk V, Pope J, Haraoui P, Hitchon C, Thorne C, Keystone E, Gilles Boire. Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor Fluctuate in Early Inflammatory Arthritis and do not Predict Disease Outcomes. J Rheumatol 2013;40(8):1259-1267.
Kinloch AJ, Brintnell W, Alzabin S, Wilson E, Barra L, Wegner N, Bell DA, Cairns E, Venables PJ. Immunisation with Porphyromonas gingivalis enolase induces autoimmunity to mammalian alpha-enolase and arthritis in DR4IE transgenic mice. Arthritis Rheum. 2011 Dec;63(12):3818-23.